Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.59 |
| ▸ | MTOR | P42345 | 2/20 | 0.57 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.57 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | STK16 | O75716 | 1/20 | 0.57 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284086 | 1.00 | PIK3CA (0.69) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1286465 | 0.94 | PIK3CA (0.70) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1286458 | 0.94 | PIK3CA (0.70) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL13137371 | 0.93 | PIK3CA (0.66) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1687434 | 0.91 | PIK3CA (0.68) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL30130770 | 0.90 | PIK3CA (0.67) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1286361 | 0.89 | PIK3CA (0.73) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1859783 | 0.88 | PIK3CA (0.74) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL25297285 | 0.88 | PIK3CA (0.75) | PIK3CAABCC4ABCB11PIK3CDPIK3CB | |
| SCHEMBL1621765 | 0.88 | PIK3CA (0.68) | PIK3CAABCC4ABCB11PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2021-07-15 | — | — | US | disclosed |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200339593-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10676482-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190352310-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2019-11-21 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| EP-2385832-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | Curis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8040979-B2 | Generating a phase value for a complex signal | INFINEON TECHNOLOGIES AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885ABCC4 3968/4885ABCB11 4719/4885 |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885ABCC4 3968/4885ABCB11 4719/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885ABCC4 3968/4885ABCB11 4719/4885 |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885ABCC4 3968/4885ABCB11 4719/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-20200339593-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885ABCC4 3968/4885ABCB11 4719/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-10676482-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | KRAS, HRAS, KSR2 | PIK3CA 31/4885ABCC4 2836/4885ABCB11 3570/4885 |
| US-20190352310-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885ABCC4 3948/4885ABCB11 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.